True Wealth Design’s Q32 Bio QTTB Stock Holding History

True Wealth Design’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-67	Closed	-$100	–	2912
2025 Q2	$100	Buy	67 +60	+857%	+$102	﹤0.01%	2239
2025 Q1	$12	Buy	+7	New	+$19	﹤0.01%	2625

Other funds holding QTTB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Trustees of Columbia University in the City of New York New York $891M AUM 17.3% 1-Year Est. Return

True Wealth Design's QTTB Position: Q3 2025 in Review

True Wealth Design sold out of Q32 Bio (QTTB) in Q3 2025, closing a stake of 67 shares — an estimated $100 sold.

True Wealth Design first reported a position in QTTB in Q1 2025 and held it in 2 quarters. The position peaked at $100 in Q2 2025. 53 funds tracked by Wall St. Rank hold QTTB as of Q3 2025.

True Wealth Design reported no remaining Q32 Bio position as of Q3 2025 after selling out during the quarter.
True Wealth Design sold 67 Q32 Bio shares in Q3 2025, an estimated $100.
True Wealth Design first reported a position in Q32 Bio in Q1 2025 and held it in 2 quarters.
True Wealth Design's Q32 Bio position peaked at $100 in Q2 2025.
53 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2025.

Based on True Wealth Design's 13F filing for Q3 2025, filed 21 Oct 2025.